Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody

IntroductionAdvanced hepatocellular carcinoma (HCC) poses significant therapeutic challenges due to chemotherapy resistance and limited efficacy of current targeted therapies. To address this unmet need, we developed a bispecific antibody (BsAb) platform targeting CD16A on natural killer (NK) cells...

Full description

Saved in:

Bibliographic Details
Main Authors:	Liu Chen, Yuankui Zhu, Mingqian Feng, Dianbao Zuo, Guoping Chen, Kangkang Ji
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	bispecific antibody NK cell engager CD16A glypican-3 hepatocellular carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1599764/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors
by: Xuqian Ma, et al.
Published: (2025-08-01)

RETRACTED ARTICLE: Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma
by: Woo-Ri Shin, et al.
Published: (2022-04-01)

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma
by: Linfu Zhou, et al.
Published: (2024-06-01)

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer
by: Kangkang Ji, et al.
Published: (2025-05-01)

Normal Glypican-3 Serum Levels Do Not Eliminate the Risk of Hepatocellular Carcinoma
by: Agnieszka Lembas, et al.
Published: (2024-09-01)

Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models
by: Yingying Lin, et al.
Published: (2025-04-01)

A high proportion of CD38 (high) CD16 (low) NK cells in colorectal cancer can interrupt immune surveillance and favor tumor growth
by: Xueling Wang, et al.
Published: (2025-07-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)

PRMT5 highly expressed on CD16 + CD56- natural killer cells is correlated with NK cells exhaustion in colorectal cancer mesenchyme
by: Zunzhen Nie, et al.
Published: (2025-03-01)

Expression features of CD16 and NKG2D receptors by NK cells, NKT cells and T lymphocytes of peripheral blood associated with female infertility
by: V. A. Mikhailova, et al.
Published: (2025-07-01)

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024-12-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins
by: Yuxin Fang, et al.
Published: (2025-04-01)

A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection
by: Yusheng Cheng, et al.
Published: (2025-05-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023-12-01)

MRI Parameters and Clinicopathologic Features in Predicting Hepatocellular Carcinomas With Aggressive-Related Marker Expression, Defined by Epithelial Cell Adhesion Molecule and Glypican-3 Status
by: Li Y, et al.
Published: (2025-03-01)

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
by: Kerry A. Whalen, et al.
Published: (2023-12-01)

CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects in bladder cancer
by: Zaineb Hassouneh, et al.
Published: (2025-08-01)

CAR-NK cell therapy: promise and challenges in solid tumors
by: Sahar Balkhi, et al.
Published: (2025-04-01)

Minor population of NK lymphocytes with CD19 coexpression
by: A. A. Kalashnikova, et al.
Published: (2024-04-01)

Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia
by: Shisen Wang, et al.
Published: (2025-07-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Persistent NK cell deficiency associated with pulmonary cryptococcosis
by: Martin Martinot, et al.
Published: (2025-01-01)

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma
by: Yuejiao Huang, et al.
Published: (2025-05-01)

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

Inverse association between dietary fiber intake and gallstone disease in U.S. adults: a cross-sectional study from the NHANES database
by: Dianbao Zuo, et al.
Published: (2025-07-01)

Bulk and single-cell RNA sequencing identify prognostic signatures related to FGFBP2+ NK cell in hepatocellular carcinoma
by: Yinbing Wu, et al.
Published: (2025-05-01)

A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c+ cells
by: Rita Szoke-Kovacs, et al.
Published: (2025-07-01)

A rare germline mutation reverses the suppressive effect of GPC5 thereby promoting lung adenocarcinoma development and tumorigenesis
by: Zhifa Zheng, et al.
Published: (2025-04-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
by: Liping Qin, et al.
Published: (2024-12-01)

Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients
by: Peng Sun, et al.
Published: (2025-06-01)

The unreversible reduced but persistent activated NK and CD8+ T cells in severe/critical COVID-19 during omicron pandemic in China
by: Ling Qin, et al.
Published: (2023-12-01)

Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01)

Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells
by: Faisal Al Agrafi, et al.
Published: (2024-12-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Influence of CD16 (FcγRIII) Expression on Peripheral Blood Mononuclear Cells on Response to Treatment with Rituximab in Pemphigus: A Cross-Sectional Study
by: Ankur Sharma, et al.
Published: (2025-07-01)

Design and functional characterization of a tetravalent NK cell-engaging bispecific antibody with enhanced half-life for CD30+ lymphoma
by: Caizhi Zhao, et al.
Published: (2025-05-01)